What is the rating for SLXN stock?

Silexion Therapeutics Corp (SLXN) has a "Avoid" rating based on our 6-factor quantitative model. It has a composite score of 34.1 and ranks #4200 out of 7,333 stocks in our coverage universe with a 1-star rating.

Is SLXN a good stock to buy?

Based on our quantitative analysis, SLXN receives a "Avoid" rating with 1 out of 5 stars. Key factors include: Quality score of 24.4, Value score of 22, and Momentum score of 40. The timing score is 36, indicating "Bearish" entry conditions. This is not investment advice - please conduct your own research.

What sector is SLXN in?

Silexion Therapeutics Corp (SLXN) operates in the Manufacturing sector, specifically in the Pharmaceutical Products industry. It has a market capitalization of $0.00 billion.

What is SLXN's P/E ratio?

SLXN has a P/E (Price-to-Earnings) ratio of 0.49x. This helps investors assess whether the stock is trading at a premium or discount relative to its earnings.

Does SLXN pay a dividend?

SLXN does not currently pay a dividend.

What is SLXN's market cap?

Silexion Therapeutics Corp (SLXN) has a market capitalization of $0.00 billion, making it a micro-cap stock.

What are the risks of investing in SLXN?

Key risk factors for SLXN include: higher volatility, and general market risk. As with all investments, there is risk of loss.

How does SLXN compare to peers?

Within the Manufacturing sector, SLXN ranks #4200 overall with a quality score of 24.4/100 and value score of 22/100.

What is SLXN's revenue growth?

Revenue growth data is not currently available for SLXN.

What is SLXN's composite score?

Silexion Therapeutics Corp (SLXN) has a composite score of 34.1/100, which places it at rank #4200 out of 7,333 stocks. This score is derived from our proprietary 6-factor quantitative model that evaluates quality, value, momentum, investment efficiency, stability, and short interest.

How does SLXN compare to the S&P 500?

SLXN ranks in the top 43% of all stocks in our coverage universe with a composite score of 34.1. This places it below the market median.

What are the bull and bear cases for SLXN?

Bull case: SLXN scores highest in short interest at 75.6/100, indicating strong performance in this area. Bear case: The weakest factor is value at 22/100, which may present a risk. Our overall assessment is Avoid with 1 out of 5 stars.

Is SLXN overvalued or undervalued?

SLXN appears overvalued based on our value factor score of 22/100. Trading at 0.5x earnings, the stock commands a premium valuation.

What is SLXN's momentum score?

SLXN has a momentum score of 40/100, placing it in the moderate category.

When is SLXN's next earnings date?

For the latest earnings date and analysis for SLXN, visit our earnings calendar or check the SLXN stock page for real-time updates. Our AI-generated earnings reports provide in-depth analysis after each quarterly report.

Is SLXN a good stock to buy right now?

Based on our 6-factor quantitative model, Silexion Therapeutics Corp (SLXN) receives a "Avoid" rating with a composite score of 34.1/100. It is ranked #4200 out of 7,333 stocks. Key factor scores: Quality 24/100, Value 22/100, Momentum 40/100. The timing signal is "Bearish". This is quantitative analysis only — not investment advice.

What is the stock rating for SLXN?

Silexion Therapeutics Corp (SLXN) has a "Avoid" rating and 1-star score. The composite score of 34.1 ranks it #4200 among 7,333 U.S. stocks. Ratings are updated weekly using academically-proven factor models.

What sector is SLXN in?

Silexion Therapeutics Corp operates in the Manufacturing sector (Pharmaceutical Products industry) with a market cap of $4 million. It is classified as a micro-cap stock.

Does SLXN pay a dividend?

SLXN does not currently pay a regular dividend. The company may be reinvesting profits for growth.

What is SLXN's P/E ratio?

SLXN has a trailing P/E ratio of 0.49x. The Manufacturing sector average is 22.3x. This below-average P/E may indicate the stock is undervalued.

How profitable is SLXN?

SLXN's quality factor score is 24/100. Gross margin: 100.0%. ROE: -277.5% vs sector average -1.9%. High margins suggest pricing power and competitive moats.

How is SLXN valued compared to peers?

SLXN's value factor score is 22/100 (higher = cheaper). Key multiples: P/E 0.5x. Trading at a premium relative to peers.

What is SLXN's debt level?

SLXN's debt-to-equity ratio is 66%. Sector average: 0%. Moderate leverage is normal for established companies.

SLXN has a beta of 0.37, meaning it is less volatile than the market. Stability score: 30/100.

Does SLXN have high short interest?

SLXN's short interest factor score is 76/100 (higher = less short selling). Very low short interest — broad institutional consensus.

SLXN Stock Analysis — Silexion Therapeutics Corp Price Target & Forecast 2026

IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.

HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.

RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.

SLXN Stock Analysis — Silexion Therapeutics Corp Price Target & Forecast 2026 | Blank Capital Research

Sector

Manufacturing

Industry

Pharmaceutical Products

Market Cap

$4M

Leadership

Ilan Hadar

Business Summary

Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.

Operations

Headcount

—

Location

Fundamental Spot Check

Context: 2025

Valuation

Market Cap

$4M

P/E Ratio

0.5xOutperforming

P/B Ratio

0.70xOutperforming

P/S Ratio

57.38xLagging

EV/EBITDA

Dividend Yield

0.00%

Efficiency & Risk

Gross Margin

100.0%Outperforming

Operating Margin

-32044.0%Lagging

ROE

-277.5%Lagging

Rev Growth (YoY)

Debt/Equity

66.00xLagging

Beta

0.37

Red = Sector Laggard

Black = Market Average

Revenue Breakdown

Strategic Timing Audit

WEAK

0/6

Negative Alignment — Extreme Caution

Quantitative Factor Convergence Analysis Verified

Momentum

40th pctl

Intelligence Feed

BenzingaJan 29 Negative

US Futures Point To Cautious Start As Investors Await Fed's Rate Decision: Tesla, Microsoft, Meta Among Stocks In Focus Ahead Of Earnings

U.S. stock futures were mixed ahead of the Federal Reserve's interest rate decision and key earnings reports from major tech companies. Investors are cautious as they await the Fed's policy announcement and guidance.

yahooJan 21 Negative

Silexion Therapeutics to Attend 7th Annual RNAi-Based Therapeutics Summit

Grand Cayman, Cayman Island, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (“Silexion” or the “Company”), a clinical-stage, oncology-focused biotechnology company, today announced that Company management, including CEO Ilan Hadar, will attend the 7th RNAi-Based Therapeutics Summit, taking place January 27-29 in Boston, MA. The 7th RNAi-Based Therapeutics Summit is the industry's premier forum inviting drug developers to discuss RNA-based therapeutics for neurological, metabolic,

yahooJan 6 Neutral

Silexion Therapeutics Releases CEO Letter to Shareholders Highlighting 2025’s Significant Achievements and Outlining Upcoming Milestones for 2026

SIL204 Demonstrated Significant Tumor Inhibition in Positive Pre Clinical Studies with Activity Across Pancreatic, Colorectal, and Lung Cancer Models Company’s Platform Seeks to Address an Estimated $30+ Billion Global KRAS-Driven Cancer Market with Pan-KRAS Therapeutic Platform Initiation of Phase 2/3 Clinical Trial in LAPC Planned for H1 2026 Following Positive Regulatory Feedback and Successful Toxicology Studies Grand Cayman, Cayman Islands, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Silexion Therape

benzinga.comDec 30 Neutral

12 Health Care Stocks Moving In Tuesday's After-Market Session

Earnings Call Transcripts

Unlock Valuation Tools

Get full access to institutional-quality research tools with Blank Capital Pro.

Upgrade to Pro

Starting at $19.99/mo

Financial Intelligence Ledger

Verified SEC Filings Aggregate • SLXN

Export

Metric Entity	10Y Historical Trend	2024	2023
Revenue		$28K	$0
Cost of Revenue	-	—	—
Gross Profit	-	—	$0
R&D Expense		$6M56.8%	$4M
Operating Expenses	-	—	—
Operating Income		-$13M168.6%	-$5M
Interest Expense	-	—	—
Tax Provision		$10K68.8%	$32K
EBITDA		-$13M149.9%	-$5M
Net Income		-$17M223.4%	-$5M
EPS (Diluted)		$26.3640.4%	$44.23

SEC EDGAR Repository

Direct unfiltered access to 10-K, 10-Q and 8-K filings for SLXN.

Open Regulatory Dossier

Data Integrity Notice

Figures adjusted for stock splits and restatements where applicable.

TTM (Trailing Twelve Months) data updates within 48 hours of quarterly filings.

Execution Benchmarks Audit

Gross Margin

Core pricing power

+127% SCTR

100.0%

Sector Avg: 44.1%

Operating Margin

Operating efficiency

-1276753% SCTR

-32044.0%

Sector Avg: 2.5%

Return on Equity

Equity efficiency

+14504% SCTR

-277.5%

Sector Avg: -1.9%

Debt/Equity

Financial leverage

-31329% SCTR

66.0%

Sector Avg: 0.2%

Dividend Yield

Direct cash return

-NaN% SCTR

0.0%

Sector Avg: 0.0%

Financial History

Forensic Accounting Audit

Watchlist

Margin Integritymedium RISK

High margin volatility — erratic forensic earnings quality

Algorithmic red flag detection based on regulatory SEC filings.

Unlock Financial Statements

Get full access to institutional-quality research tools with Blank Capital Pro.

Upgrade to Pro

Starting at $19.99/mo

Shareholder Returns

Capital Allocation audit

Smart Money Conviction

Neutral

Synthesized from recent 13F filings, Form 4 insider transactions, and outstanding short interest metrics.

Governance Audit

Weak Index

WeakModerateStrong

Lower quality and stability scores may indicate governance concerns. Verified against factor-based integrity benchmarks.

Executive Operations

CEO: Ilan Hadar

Insider alignment Audit

No recent insider transactions available for SLXN

Major Institutional Blocks

Top 5 Holders

Institutional cap table data requires verified 13F filing feeds.

Access SEC 13F Dossier →

Form 4 Filings

Recent Activity

Insider transaction data currently awaiting regulatory verification.

Access SEC Form 4 Dossier →

Regulatory Disclosure Vault

Proxy Statement (DEF 14A)

Exec Comp, Board Nominees, Proposals

Annual Report (10-K)

MD&A, Risk Factors, Strategy

Institutional Holders (13F)

Loading institutional data...

Insider Liquidity

Short Interest audit

SEC Risk Factors

Unlock Governance & Ownership

Get full access to institutional-quality research tools with Blank Capital Pro.

Upgrade to Pro

Starting at $19.99/mo

Unlock Factor Analysis

Get full access to institutional-quality research tools with Blank Capital Pro.

Upgrade to Pro

Starting at $19.99/mo

Unlock Investment Thesis

Get full access to institutional-quality research tools with Blank Capital Pro.

Upgrade to Pro

Starting at $19.99/mo

Institutional Peer Matrix

Top Manufacturing Universe

Stock	Rating	Score▼	Quality	Value	Momentum	P/E	EV/EBITDA	ROE	ROA	Gross Mgn	Op Mgn	Net Mgn	Rev Growth	Div Yield	D/E	Mkt Cap	AUDIT
$UL UNILEVER PLC		78	96	98	59	-	-	-	-	-	-	-	-	-	-	$0	VS
$ASML ASML HOLDING NV		77	89	86	83	-	-	-	-	-	-	-	-	-	-	$0	VS
$ESLT ELBIT SYSTEMS LTD		76	81	87	85	-	-	-	-	-	-	-	-	-	-	$0	VS
$MT ArcelorMittal		75	71	98	85	-	-	-	-	-	-	-	-	-	-	$0	VS
$AMAT APPLIED MATERIALS INC /DE		75	85	87	84	20.9x	13.6x	32.9%	20.5%	48.8%	30.6%	24.4%	7.7%	0.9%	32.0x	$148.6B	VS
$SIMO Silicon Motion Technology CORP		75	84	86	85	-	-	-	-	-	-	-	-	-	-	$0	VS
$CODA Coda Octopus Group, Inc.		74	83	90	79	16.3x	11.9x	7.4%	7.5%	68.3%	19.5%	18.2%	29.0%	0.0%	0.0x	$84M	VS
$GSK GSK plc		74	84	90	70	-	-	-	-	-	-	-	-	-	-	$0	VS
$EFXT Enerflex Ltd.		74	80	91	83	-	-	-	-	-	-	-	-	-	-	$0	VS
$BUD Anheuser-Busch InBev SA/NV		74	84	97	63	-	-	-	-	-	-	-	-	-	-	$0	VS
$SLXN Silexion Therapeutics Corp		34	24	22	40	0.5x	-	-277.5%	-166.7%	100.0%	-32044.0%	-33600.9%	-	0.0%	66.0x	$4M
SECTOR BENCH	-	-	-	-	-	22.3x	11.5x	-1.9%	0.9%	44.1%	2.5%	1.0%	6.7%	0.0%	0.2x	-	REF

Access Full Manufacturing Intelligence Archive →

Lateral Comparison Mesh

$SLXN / $UL AUDIT $SLXN / $ASML AUDIT $SLXN / $ESLT AUDIT $SLXN / $MT AUDIT $SLXN / $AMAT AUDIT

Market Intelligence FAQ

Silexion Therapeutics Corp (SLXN) receives a "Avoid" rating with a composite score of 34.1/100. It ranks #4200 out of 7,333 stocks in our coverage universe and carries a 1-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.

Full Research Publication

Equity Research Analysis: Silexion Therapeutics Corp (SLXN)

FEBRUARY 2026|Blank Capital Research Unit|Spot: $1.52

Price$1.52

Composite Score34.1/100

RatingAVOID (1★)

Rank#4200 OF 7,333

Market Cap$4M

Comments

Institutional Audit

Feb 25, 2026

Silexion Therapeutics Corp

34.1

Executive Summary

Our quantitative model flags Silexion Therapeutics Corp with an Avoid rating, assigning a composite score of 34.1/100 and 1 out of 5 stars. Ranked #4200 of 7,333 stocks, SLXN falls in the bottom tier across key factors. Historically, stocks with this profile have faced elevated risk of underperformance and capital loss.

Business Quality

Silexion Therapeutics Corp registers a weak quality score of just 24/100, indicating significant profitability challenges. The company reports a return on equity of -277.5% (sector avg: -1.9%), gross margins of 100.0% (sector avg: 44.1%), net margins of -33600.9% (sector avg: 1.0%). Low quality scores are often associated with businesses in turnaround mode, early-stage growth, or structurally challenged industries.

Intrinsic Valuation

SLXN registers a value score of just 22/100, suggesting the stock trades at a significant premium to its fundamental metrics. Key valuation metrics include a P/E ratio of 0.49x, a P/B ratio of 0.70x. High-premium valuations like this require strong future execution to avoid multiple compression, and downside risk is elevated if growth disappoints.

Capital Reinvestment

Silexion Therapeutics Corp's investment score of 23/100 suggests limited reinvestment activity. Key growth metrics include a return on assets of -166.7% (sector: 0.9%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.

Market Momentum

SLXN is currently showing below-average momentum at 40/100, which may indicate weakening institutional interest or negative sentiment shifts. Revenue growth data is not currently available, while a beta of 0.37 reflects its sensitivity to broader market moves. Investors should note that declining momentum can precede further price weakness, though contrarian opportunities sometimes emerge at these levels.

Balance Sheet Health

SLXN's stability score of 30/100 signals elevated volatility and/or leverage concerns. Key stability metrics include a beta of 0.37 and a debt-to-equity ratio of 66.00x (sector avg: 0.2x). Investors should be prepared for wider-than-average price swings and consider position sizing accordingly to manage portfolio risk.

Institutional Risk Profile

SLXN carries a short interest score of 76/100, indicating moderate short selling activity. This is a neutral reading — not enough to signal systemic bearishness, but worth monitoring. Specific risk factors include elevated leverage (D/E: 66.00x), micro-cap liquidity risk. At $4M market cap (micro-cap), Silexion Therapeutics Corp offers reasonable institutional liquidity.

Sector Benchmark Analysis

Silexion Therapeutics Corp is a micro-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #4200 of 7,333 overall (43rd percentile). Key comparisons include ROE of -277.5% trailing the -1.9% sector median and operating margins of -32044.0% below the 2.5% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.

Comparative Research Mesh

SLXN VS S&P 500 (SPY)TOP MANUFACTURING PEERS

Strategic Alternatives

While SLXN currently exhibits a AVOID profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.

View Top Manufacturing Alpha →

SLXN

Silexion Therapeutics Corp

Business Summary

Operations

Location

Fundamental Spot Check

Valuation

Efficiency & Risk

Intelligence Feed

US Futures Point To Cautious Start As Investors Await Fed's Rate Decision: Tesla, Microsoft, Meta Among Stocks In Focus Ahead Of Earnings

Silexion Therapeutics to Attend 7th Annual RNAi-Based Therapeutics Summit

Silexion Therapeutics Releases CEO Letter to Shareholders Highlighting 2025’s Significant Achievements and Outlining Upcoming Milestones for 2026

12 Health Care Stocks Moving In Tuesday's After-Market Session

Unlock Valuation Tools

Unlock Financial Statements

Unlock Governance & Ownership

Unlock Factor Analysis

Unlock Investment Thesis

Lateral Comparison Mesh

Comments

SEC Risk Factors

Unlock Performance & Technicals

Economic Moat Audit

Economic Value Creation

Margin Superiority

Reinvestment Efficiency

Growth Durability

Financial Resilience

Uncertainty Audit

BEAR THESIS

01Executive Summary

02Strategy & Outlook

Risk / Reward Variance

Research Verdict

Related Stocks

Executive Summary

Business Quality

Intrinsic Valuation

Capital Reinvestment

Market Momentum

Balance Sheet Health

Institutional Risk Profile

Sector Benchmark Analysis

Comparative Research Mesh

Strategic Alternatives

Factor Dispersion Audit

Sector Variance Findings

Market Intel

Intelligence Feed

US Futures Point To Cautious Start As Investors Await Fed's Rate Decision: Tesla, Microsoft, Meta Among Stocks In Focus Ahead Of Earnings

Silexion Therapeutics to Attend 7th Annual RNAi-Based Therapeutics Summit

Silexion Therapeutics Releases CEO Letter to Shareholders Highlighting 2025’s Significant Achievements and Outlining Upcoming Milestones for 2026

12 Health Care Stocks Moving In Tuesday's After-Market Session